What exactly is fezolinetant?

Fezolinetant is a new type of neurokinin 3 (NK3) receptor antagonist, developed by the Japanese company Eisai and approved by the US FDA in 2023 under the trade name "VEOZAH". The birth of this drug marks an important breakthrough in the field of non-hormonal therapy in the treatment of menopause, especially for vasomotor symptoms such as hot flashes and night sweats, providing a new option for women who are unable or unwilling to use estrogen replacement therapy.

The core mechanism is to block the binding of neurokininB to NK3 receptors, thereby inhibiting the overactivity of hypothalamic KNDy neurons. After menopausal women's estrogen decreases, the activity of KNDy neurons increases, causing temperature regulation disorders, manifested by frequent hot flashes. Fezolinetant restores body temperature balance through "neuroregulation" rather than "hormone supplementation", thus achieving a good balance between therapeutic effect and safety.

In clinical application,Fezolinetant is suitable for the treatment of moderate to severe hot flashes in menopausal women. It works quickly, with symptom improvement usually seen within a few days to two weeks of taking it. Compared with estrogen therapy, the drug is not hormone-dependent and does not increase the risk of breast cancer or blood clots. The usual dose of the drug is 45 mg orally once daily and does not need to be taken with food.

From a metabolic perspective,Fezolinetant is mainly metabolized by the liver enzyme CYP1A2, so concurrent use of strong CYP1A2 inhibitors (such as fluvoxamine) should be avoided during medication. Common side effects include mild headache, abdominal pain, elevated liver enzymes, etc., but most are reversible. Its safety has been verified in multiple international clinical studies and it has little impact on the cardiovascular system.

In general, fizonitant is a non-hormonal central nervous system modulating drug that opens up new ideas for menopausal management by precisely targetingNK3 receptors, and is especially suitable for women who have concerns or contraindications for hormone therapy.

Reference materials:https://www.veozah.com/